COLLEGEVILLE, Pa. (AP) — A Wyeth unit and biopharmaceutical company Ambrx Inc. said Friday that they have teamed up to find and commercialize protein drug candidates for three unnamed targets. Ambrx said it will work with Wyeth Pharmaceuticals and use its latest biologics platform findings as part of the alliance. Ambrx expects an undisclosed amount in near-term payments from an upfront commitment, target loading fees and research funding. The company may also receive milestone payments and tiered royalties on product sales. Wyeth Pharmaceuticals, which will work with Ambrx on the project, has products in categories such as women’s health care, infectious disease, gastrointestinal health, central nervous system and oncology.
